Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  1995-08-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0360-3016(95)00154-QPMID 7543892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Applied Logistic Regression: Hosmer/Applied Logistic Regression

  2005cited by this paper
• Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.

  1995cited by this paper
• The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.

  1995cited by this paper
• The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?

  1995cited by this paper
• The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

  1994cited by this paper
• Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.

  1994cited by this paper
• Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

  1994cited by this paper
• Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.

  1994cited by this paper
• The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.

  1994cited by this paper
• Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.

  1994cited by this paper
• Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment.

  1994cited by this paper
• Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.

  1994cited by this paper
• Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy.

  1994cited by this paper
• Impact of radical prostatectomy in the management of clinically localized disease.

  1994cited by this paper
• Control of prostate cancer with radiotherapy: long-term results.

  1994cited by this paper
• Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome.

  1994cited by this paper
• Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.

  1994cited by this paper
• 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.

  1994cited by this paper
• Trends in prostate cancer care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American college of surgeons commission on cancer

  1993cited by this paper
• Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapy

  1993cited by this paper
• Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer.

  1993cited by this paper
• Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.

  1993cited by this paper
• Evaluation of the current incidence of nodal metastasis from prostate cancer

  1993cited by this paper
• Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

  1993cited by this paper
• Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

  1993cited by this paper
• Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

  1992cited by this paper
• Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer.

  1992cited by this paper
• Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.

  1992cited by this paper
• Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.

  1992cited by this paper
• The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy

  1991cited by this paper
• Survivorship Analysis for Clinical Studies

  1990cited by this paper
• Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up.

  1990cited by this paper
• The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels.

  1990cited by this paper
• Prostate specific antigen and local recurrence after radical prostatectomy.

  1990cited by this paper
• Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.

  1990cited by this paper
• Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate.

  1990cited by this paper
• Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate.

  1989cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

  1989cited by this paper
• Status of radiation treatment of prostate cancer at Stanford University.

  1989cited by this paper
• Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981).

  1988cited by this paper
• Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

  1988cited by this paper
• The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate.

  1988cited by this paper
• Radiotherapy of prostate carcinoma: results of treatment and complications.

  1987cited by this paper
• Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation

  1987cited by this paper
• Long-term autopsy findings following radical prostatectomy.

  1987cited by this paper
• The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer.

  1986cited by this paper
• Improving the therapeutic ratio of external beam irradiation for carcinoma of the prostate.

  1985cited by this paper
• Radiotherapy for prostate carcinoma: the JCRT experience (1968-1978). II. Factors related to tumor control and complications.

  1985cited by this paper
• Carcinoma of the prostate: Results of post‐irradiation biopsy

  1984cited by this paper
• External beam radiotherapy in cancer of the prostate. The University of Arizona experience.

  1984cited by this paper
• Estimation of confidence limits for the cumulative probability of survival in life table analysis.

  1978cited by this paper
• The significance of needle biopsy after irradiation for stage c adenocarcinoma of the prostate

  1977cited by this paper

• Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy

  2023cites this paper
• Management strategies for radio-recurrent prostate cancer: a comprehensive review

  2023cites this paper
• Robotic Salvage Prostatectomy: a Contemporary Review

  2021cites this paper
• Salvage high dose rate brachytherapy for recurrent prostate cancer after definitive radiation.

  2021cites this paper
• Therapie bei isoliertem PSA-Anstieg

  2020cites this paper
• Nerve‐sparing in salvage robot‐assisted prostatectomy: surgical technique, oncological and functional outcomes at a single high‐volume institution

  2018cites this paper
• Perioperative Complications and Long-Term Outcome of Salvage Radical Prostatectomy Compared to Primary Radical Prostatectomy

  2017cites this paper
• Traitements complémentaires de la chirurgie du cancer de la prostate et chirurgie de la récidive

  2015cites this paper
• Emerging treatments for recurrent prostate cancer.

  2015cites this paper
• Salvage robot assisted radical prostatectomy: A propensity matched study of perioperative, oncological and functional outcomes.

  2015cites this paper
• Reirradiation of locally recurrent prostate cancer after primary radiotherapy

  2015cites this paper
• [Treatments around surgery of prostate cancer and surgery of recurrence].

  2015cites this paper
• Traitements de rattrapage après irradiation prostatique : place de l’urologue

  2014cites this paper
• [Salvage treatments following prostate radiation therapy: role of the urologist].

  2014cites this paper
• Salvage Robotic-Assisted Laparoscopic Radical Prostatectomy

  2014cites this paper
• Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options.

  2014cites this paper
• Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options☆

  2014cites this paper
• Salvage robotic radical prostatectomy

  2014cites this paper
• Salvage robotic assisted laparoscopic radical prostatectomy: indications and outcomes

  2013cites this paper
• Seminal vesicle involvement at salvage radical prostatectomy

  2013cites this paper
• Accuracy of post‐radiotherapy biopsy before salvage radical prostatectomy

  2013cites this paper
• Management of patients with biochemical recurrence after local therapy for prostate cancer.

  2013cites this paper
• Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience.

  2012cites this paper
• [Salvage high energy focalized ultrasound (HIFU) in prostate cancer after radiotherapy].

  2012cites this paper
• Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy

  2012cites this paper
• High-risk prostate cancer: from definition to contemporary management.

  2012cites this paper
• Management of biochemical recurrence after localized treatment for prostate cancer

  2012cites this paper
• Radiorekürren prostat kanseri için salvage terapiler

  2011cites this paper
• Preliminary Analysis of the Feasibility and Safety of Salvage Robot-Assisted Radical Prostatectomy After Radiation Failure: Multi-Institutional Perioperative and Short-Term Functional Outcomes

  2011cites this paper
• 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.

  2011cites this paper
• Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy

  2010cites this paper
• Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.

  2010cites this paper
• La prostata operata: il sospetto clinico di recidiva

  2010cites this paper
• Reoperative Surgery for Prostate Cancer

  2009cites this paper
• Radical Laparoscopic Salvage Prostatectomy: Medium-Term Functional and Oncological Results

  2009cites this paper
• Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.

  2009cites this paper
• Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy

  2009cites this paper
• RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study

  2009cites this paper
• The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery

  2008cites this paper
• Robotic salvage retropubic prostatectomy after radiation/brachytherapy: initial results

  2008cites this paper
• The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies.

  2007cites this paper
• Locally ablative therapies for primary radiation failures: A review and critical assessment of the efficacy

  2007cites this paper
• Therapy of Treatment Failure After Curative Treatment of Prostate Cancer

  2006cites this paper
• Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.

  2006cites this paper
• Braquiterapia de alta taxa de dose no tratamento do carcinoma da próstata: análise da toxicidade aguda e do comportamento bioquímico

  2006cites this paper
• GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.

  2005cites this paper
• Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.

  2005cites this paper
• Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.

  2005cites this paper
• Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy.

  2004cites this paper
• Clinical aspects of bone metastases in prostate cancer.

  2004cites this paper
• Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy

  2004cites this paper
• Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

  2004cites this paper
• Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer.

  2003cites this paper
• Management of high-risk populations with locally advanced prostate cancer.

  2003cites this paper
• Salvage radical prostatectomy: refinement of an effective procedure.

  2003cites this paper
• Chemotherapy for localized, high-risk prostate cancer.

  2003cites this paper
• ANÀLISI PROSPECTIVA DE LA TOXICITAT I DE L'ÍNDEX TERAPÈUTIC EN EL TRACTAMENT AMB IRRADIACIÓ EXTERNA DEL CÀNCER DE PRÒSTATA. INFLUÈNCIA DEL FACTOR EDAT.

  2003cites this paper
• In response to Drs. Lawrence and Crawford

  2003cites this paper
• Surveillance clinique et biologique aprs radiothrapie pour cancer de la prostate localis

  2002cites this paper
• [Clinical and biological surveillance after radiotherapy for localized prostate cancer].

  2002cites this paper
• Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer.

  2002cites this paper
• Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.

  2002cites this paper
• Early diagnosis and treatment of prostate cancer.

  2001cites this paper
• Prognostic significance of melanoma inhibiting activity levels in malignant melanoma

  2001cites this paper
• [Multicenter study on dose escalation with conformal and conventional radiotherapy for the treatment of localized prostatic cancer. Preliminary results of tolerance and quality of life].

  2001cites this paper
• Factores pronósticos en los tumores urológicos Prognostic factors in urological tumours

  2000cites this paper
• Serum testosterone is not a correlate of prostate cancer lymph node involvement, but does predict biochemical failure for lymph node positive disease.

  2000cites this paper
• Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation.

  2000cites this paper
• Therapeutic options in locally defined or advanced prostate cancer.

  1999cites this paper
• The challenge of locally advanced prostate cancer.

  1999cites this paper
• Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy

  1999cites this paper
• A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer.

  1999cites this paper
• PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention.

  1999cites this paper
• Treatment of locally advanced prostate cancer: is chemotherapy the next step?

  1999cites this paper
• Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.

  1999cites this paper
• Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy.

  1999cites this paper
• Prognostic value of prostate specific antigen before, during and after radiotherapy.

  1998cites this paper
• Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure.

  1998cites this paper
• [Radiotherapy of localized cancer of the prostate: current status and new strategies].

  1998cites this paper
• Percent free prostate-specific antigen after radiotherapy for prostate cancer.

  1998cites this paper
• Therapeutic Options in Locally Defined or Advanced Prostate Cancer

  1998cites this paper
• Radical radiotherapy of localised prostate cancer: the relationship between radiation dose and survival.

  1998cites this paper
• Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: a comprehensive review of the literature.

  1998cites this paper
• Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.

  1997cites this paper
• A pharmacoeconomic evaluation of staging modalities for patients with newly diagnosed and occult recurrent adenocarcinoma of the prostate.

  1997cites this paper
• Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.

  1997cites this paper
• Indications et résultats de la radiothérapie exclusive dans les formes précoces d'adénocarcinome prostatique

  1997cites this paper
• Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.

  1997cites this paper
• External beam radiotherapy dose response of prostate cancer.

  1997cites this paper
• Radiotherapy for localized prostate carcinoma

  1997cites this paper
• Prognostic factors for clinically localized prostate carcinoma

  1997cites this paper
• Should Screening for Prostate Cancer Be Routinely Practised in 1997? the Argument Against

  1997cites this paper
• Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.

  1997cites this paper
• [Indications and results of exclusive radiotherapy in early prostatic adenocarcinoma].

  1997cites this paper
• Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation

  1997cites this paper
• Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.

  1997cites this paper
• Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy

  1996cites this paper
• Should asymptomatic progression following definitive local treatment for prostate cancer be treated?

  1996cites this paper
• Radiotherapy in prostate cancer treatment

  year unknowncites this paper